Eli Lilly and Co. received approval from the FDA for Cymbalta (duloxetine HCl) for the management of fibromyalgia, a chronic widespread pain disorder. Cymbalta is the first serotonin-norepinephrine reuptake inhibitor that has shown efficacy in reducing pain in patients with fibromyalgia. Cymbalta is also approved for the management of diabetic peripheral neuropathic pain (DPNP), the treatment of major depressive disorder, and generalized anxiety disorder.

“The approval of Cymbalta is important because it provides physicians and patients with a new treatment option shown to help reduce pain and improve functioning in this difficult-to-treat disorder,” said Madelaine Wohlreich, M.D., medical advisor and research physician at Lilly.